DOCSLIB.ORG

Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib Jennifer E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib Jennifer E Published OnlineFirst December 19, 2016; DOI: 10.1158/1078-0432.CCR-16-2022 Cancer Therapy: Preclinical Clinical Cancer Research Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib Jennifer E. Amengual1, Sathyen A. Prabhu1, Maximilian Lombardo1, Kelly Zullo1, Paul M. Johannet2, Yulissa Gonzalez1, Luigi Scotto1, Xavier Jirau Serrano1, Ying Wei3, Jimmy Duong3, Renu Nandakumar4, Serge Cremers4, Akanksha Verma5, Olivier Elemento5, and Owen A. O'Connor1 Abstract Purpose: Pan-class I/II histone deacetylase (HDAC) inhi- Results: Systematic incremental increases in drug exposure bitors are effective treatments for select lymphomas. led to the development of distinct resistant cell lines with IC50 Isoform-selective HDAC inhibitors are emerging as poten- values 10- to 20-fold greater than that for parental lines. GEP tially more targeted agents. ACY-1215 (ricolinostat) is a revealed upregulation of MAPK10, HELIOS, HDAC9, and FYN, first-in-class selective HDAC6 inhibitor. To better under- as well as downregulation of SH3BP5 and LCK. Gene-set stand the discrete function of HDAC6 and its role in lym- enrichment analysis (GSEA) revealed modulation of the BTK phoma, we developed a lymphoma cell line resistant to pathway.IbrutinibwasfoundtobesynergisticwithACY-1215 ACY-1215. in cell lines as well as in 3 primary patient samples of lym- Experimental Design: The diffuse large B-cell lymphoma cell phoma. In vivo confirmation of antitumor synergy was dem- line OCI-Ly10 was exposed to increasing concentrations of onstratedwithaxenograftofDLBCL. ACY-1215 over an extended period of time, leading to the Conclusions: The development of this ACY-1215–resistant development of a resistant cell line. Gene expression profiling cell line has provided valuable insights into the mechanistic (GEP) was performed to investigate differentially expressed role of HDAC6 in lymphoma and offered a novel method to genes. Combination studies of ACY-1215 and ibrutinib were identify rational synergistic drug combinations. Translation of performed in cell lines, primary human lymphoma tissue, and these findings to the clinic is underway. Clin Cancer Res; 1–13. a xenograft mouse model. Ó2016 AACR. Introduction belongs to the class 2b family of HDACs and differs from other HDACs in that it resides predominantly in the cytoplasm. Pan-class I/II histone deacetylase (HDAC) inhibitors have It is known to play a role in protein homeostasis and the proven to be successful agents for the treatment of lymphoma, unfolded protein response (UPR; refs. 6, 7). HDAC6 inhibition though their clinical application has been restricted predom- has demonstrated activity in preclinical models of lymphoma inantly to the T-cell lymphomas (1–5). While the precise role of and multiple myeloma and is presently being studied in clinical individual HDAC isoforms in lymphoma has remained an area studies both as a single agent and in combination. Although of active research, isoform-selective HDAC inhibitors have very well tolerated clinically, activity as a single agent has been begun to emerge. The first example of this is ACY-1215 (rico- limited and combination strategies have proven more effica- linostat), an isoform-selective HDAC6 inhibitor. HDAC6 cious thus far. Combinations of ACY-1215 with lenalidomide, pomalidomide, and bortezomib are presently in clinical study – 1Center for Lymphoid Malignancies, Columbia University Medical Center, New for patients with multiple myeloma (8 11). York, New York. 2Stanford University School of Medicine, Stanford, California. In an effort to gain insights into the role of HDAC6 in lym- 3Department of Biostatistics, Mailman School of Public Health, Columbia Uni- phoma and to identify novel pathways that may be synergistic versity, New York, New York. 4Division of Clinical Pathology, Department of with ACY-1215, a lymphoma cell line was developed to be Pathology and Cell Biology, Columbia University Medical Center, New York, New 5 resistant to the HDAC6-selective inhibitor ACY-1215. Drug resis- York. Institute for Computational Biomedicine, Weill Cornell Medical College, tance can be defined as intrinsic or acquired. Intrinsic drug New York, New York. resistance is often difficult to demonstrate in tissue culture, and Note: Supplementary data for this article are available at Clinical Cancer is defined as cells that harbor preexisting conditions which render Research Online (http://clincancerres.aacrjournals.org/). them unresponsive to a particular drug or drug combination. Corresponding Author: Jennifer E. Amengual, Columbia University, 51 W 51st Acquired drug resistance typically emerges in stages, and at least Street, Suite 200, New York, NY 10019. Phone: 212-326-5720; Fax: 212-326-5725; theoretically is attributed to the emergence of pathways that E-mail: [email protected] bypass the inhibition posed by a particular drug. We reasoned doi: 10.1158/1078-0432.CCR-16-2022 that if the emergence of compensatory pathways could mitigate Ó2016 American Association for Cancer Research. sensitivity to exposure of a specific drug, then such pathways www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst December 19, 2016; DOI: 10.1158/1078-0432.CCR-16-2022 Amengual et al. in DMSO. Deuterated internal standard ibrutinib-d5 was Translational Relevance purchased from TLC Pharmaceutical Standards Ltd. All sol- To better understand the function of HDAC6 and its role in vents and other chemicals for sample extraction were LC/MS lymphoma, we developed lymphoma cell lines resistant to the grade. selective HDAC6 inhibitor ACY-1215. ACY-1215 has demon- strated activity in preclinical models of multiple myeloma and Cell lines and culture lymphoma and is currently being studied clinically for both of Hbl-1, OCI-Ly10, and Riva are activated B-cell (ABC) DLBCL fi these diseases. Gene expression pro ling was performed on cell lines; OCI-Ly1, OCI-Ly7, Su-DHL-6 are germinal center the resistant line and compared with the parental line which (GC) DLBCL cell lines; JVM2, MAVER, Hbl-2, Jeko-1, and Rec-1 pointed to modulation of the BTK pathway revealing a poten- are mantle cell lymphoma (MCL) cell lines; HH and H9 are fi tial drug partner. Synergy was con rmed with the combination T-cell lymphoma (TCL) cell lines. Su-DHL-6, HBL-1, Riva, of ACY-1215 and ibrutinib in lymphoma cell lines, primary HBL2, Jeko-1, Rec-1, MAVER, HH, and H9 were obtained from human lymphoma tissue, and a mouse model of lymphoma. ATCC. OCI-Ly1, OCI-Ly7, and OCI-Ly10 were obtained from – The development and characterization of this ACY-1215 DSMZ. Su-DHL-6, Hbl-1, Hbl-2, HH, H9, Jeko-1, Jvm-2, resistant cell line has proven to be a valuable tool to advance MAVER, and Rec-1 were grown in RPMI (10% FBS). OCI-Ly7, our understanding of the functional role of HDAC6 in lym- OCI-Ly10, and Riva were grown in IMDM (10% FBS). All cell phoma. This strategy is a practical method to identify potential lines were authenticated and screened for mycoplasma using rational and synergistic drug-drug combinations. Translation the ATCC/Promega STR Authentication Testing Kit and Lonza fi of these ndings in lymphoma is now underway. MycoAlert for mycoplasma testing. Primary patient lymphoma samples were collected on an approved institutional review board (IRB) protocol. Peripheral blood was collected and peripheral blood mononuclear cells were extracted by Ficoll- could represent logical targets for rational drug-drug combina- Paque density gradient media and centrifugation. tions, preempting acquired drug resistance, at least in that specific context. This paradigm, if validated, could create a logic informing Cell viability assays the development of "rational" upfront combinations that could Cells (3 Â 105 cells/well) were incubated with 1:100 dilution of improve the efficacy of new drug combinations. drug (listed above) alone or in combination. Cell viability was We employed a strategy of gradual drug acclimation to identify assessed using the CellTiter-Glo Luminescent Cell Viability Assay a resistant cell line to try and capture emerging compensatory (Promega Corporation) and confirmed by Vi-Cell Series Cell pathways of resistance to ACY-1215. We conducted gene expres- Viability Analyzer (14, 15). The ACY-1215–resistant cell line was sion profiling (GEP) of the resistant line which was compared derived from the OCI-Ly10 cell line. OCI-Ly10 was exposed to with the parental line. The GEP data revealed modulation of the increasing concentrations of ACY-1215 over time. Systematic B-cell receptor (BCR) pathway, including downregulation of the incremental increases in drug concentration exposure led to the negative regulator of BTK (SH3BP5), increased FYN, and IKZF2. development of distinct cell lines with IC50 values 10- to 20-fold These observations led to systematic evaluation of the combina- greater than that for parental lines. tion of ACY-1215 with ibrutinib, a first-in-class BTK inhibitor, which demonstrated strong synergy. This synergy was demon- BH3 profiling strated across a large panel of cell lines, including ones represent- BH3 profiling was performed as described previously (16). ing DLBCL and mantle cell lymphoma (MCL), and primary Briefly, whole cells were permeabilized using the detergent human samples including chronic lymphocytic lymphoma digitonin which selectively permeabilizes the cell membrane, (CLL), lymphoplasmacytic lymphoma, and marginal zone lym- but not the mitochondrial membrane. BH3 peptides (synthe- in vivo phoma (MZL). In addition, an murine xenograft model of sized by the Tufts University Peptide Synthesis Core and fi fi DLBCL (OCI-LY10) con rmed the therapeutic bene ts of the Genscript) were administered to the cells in prescribed con- combination over the individual drugs. Interestingly, the UPR centrations. Depolarization of the mitochondrial membrane has been shown to be linked to the BCR pathway through IRE-1 potential was assessed by staining the cells with JC-1 dye in and XBP-1 (12, 13) in models of CLL. Work conducted in the 384-well, black, flat-bottom, nontreated plates.
Load more

Recommended publications
  • S1 Supplemental Materials Supplemental Methods Supplemental Figure 1. Immune Phenotype of Mcd19 Targeted CAR T and Dose Titratio
    Supplemental Materials Supplemental Methods Supplemental Figure 1. Immune phenotype of mCD19 targeted CAR T and dose titration of in vivo efficacy. Supplemental Figure 2. Gene expression of fluorescent-protein tagged CAR T cells. Supplemental Figure 3. Fluorescent protein tagged CAR T cells function similarly to non-tagged counterparts. Supplemental Figure 4. Transduction efficiency and immune phenotype of mCD19 targeted CAR T cells for survival study (Figure 2D). Supplemental Figure 5. Transduction efficiency and immune phenotype of CAR T cells used in irradiated CAR T study (Fig. 3B-C). Supplemental Figure 6. Differential gene expression of CD4+ m19-humBBz CAR T cells. Supplemental Figure 7. CAR expression and CD4/CD8 subsets of human CD19 targeted CAR T cells for Figure 5E-G. Supplemental Figure 8. Transduction efficiency and immune phenotype of mCD19 targeted wild type (WT) and TRAF1-/- CAR T cells used for in vivo study (Figure 6D). Supplemental Figure 9. Mutated m19-musBBz CAR T cells have increased NF-κB signaling, improved cytokine production, anti-apoptosis, and in vivo function. Supplemental Figure 10. TRAF and CAR co-expression in human CD19-targeted CAR T cells. Supplemental Figure 11. TRAF2 over-expressed h19BBz CAR T cells show similar in vivo efficacy to h19BBz CAR T cells in an aggressive leukemia model. S1 Supplemental Table 1. Probesets increased in m19z and m1928z vs m19-musBBz CAR T cells. Supplemental Table 2. Probesets increased in m19-musBBz vs m19z and m1928z CAR T cells. Supplemental Table 3. Probesets differentially expressed in m19z vs m19-musBBz CAR T cells. Supplemental Table 4. Probesets differentially expressed in m1928z vs m19-musBBz CAR T cells.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Downloaded from the UCSC Genome Browser Prior to Use ( Et Al
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.16.877365; this version posted December 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Pooled analysis of radiation hybrids identifies loci for growth and drug action in mammalian cells Arshad H. Khan1, Andy Lin2, Richard T. Wang3, Joshua S. Bloom3;4, Kenneth Lange3, Desmond J. Smith1;∗ 1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Box 951735, Los Angeles, CA 90095-1735, USA 2 Office of Information Technology, UCLA, Box 951557, 5308 MS, Los Angeles, CA 90095-1557, USA 3 Department of Human Genetics, David Geffen School of Medicine, UCLA, Box 957088, Los Angeles, CA 90095-7088, USA 4 Howard Hughes Medical Institute, David Geffen School of Medicine, UCLA, Box 957088, Los Angeles, CA 90095-7088, USA ∗ E-mail: [email protected] Running title: Pooled radiation hybrids Abstract Genetic screens in mammalian cells commonly focus on loss-of-function approaches. To evaluate the phenotypic consequences of extra gene copies, we used bulk segregant analysis (BSA) of radiation hybrid (RH) cells. We constructed six pools of RH cells, each consisting of ∼2500 independent clones, and placed the pools under selection in media with or without paclitaxel. Low pass sequencing identified 859 growth loci, 38 paclitaxel loci, 62 interaction loci and 3 loci for mitochondrial abundance at genome-wide significance. Resolution was measured as ∼30 kb, close to single-gene.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • A Graph-Theoretic Approach to Model Genomic Data and Identify Biological Modules Asscociated with Cancer Outcomes
    A Graph-Theoretic Approach to Model Genomic Data and Identify Biological Modules Asscociated with Cancer Outcomes Deanna Petrochilos A dissertation presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2013 Reading Committee: Neil Abernethy, Chair John Gennari, Ali Shojaie Program Authorized to Offer Degree: Biomedical Informatics and Health Education UMI Number: 3588836 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMI 3588836 Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, MI 48106 - 1346 ©Copyright 2013 Deanna Petrochilos University of Washington Abstract Using Graph-Based Methods to Integrate and Analyze Cancer Genomic Data Deanna Petrochilos Chair of the Supervisory Committee: Assistant Professor Neil Abernethy Biomedical Informatics and Health Education Studies of the genetic basis of complex disease present statistical and methodological challenges in the discovery of reliable and high-confidence genes that reveal biological phenomena underlying the etiology of disease or gene signatures prognostic of disease outcomes. This dissertation examines the capacity of graph-theoretical methods to model and analyze genomic information and thus facilitate using prior knowledge to create a more discrete and functionally relevant feature space.
    [Show full text]
  • From Gene Expression to Functional Foods
    cancers Article Computational Approaches for Cancer-Fighting: From Gene Expression to Functional Foods Francesco Monticolo and Maria Luisa Chiusano * Department of Agricultural Sciences, Università degli Studi di Napoli Federico II, Via Università 100, 80055 Portici, Italy; [email protected] * Correspondence: [email protected] Simple Summary: It is today widely accepted that a healthy diet can be one of the fundamental approaches to prevent the risk of cancer. To this aim, nutrigenomics studies are indeed providing a precious source of information, favoring the search for compounds that could affect gene expression in a favorable way. Here we present a computational study to select candidate compounds that could play a role in cancer prevention and care. Starting from analyses of gene expression, we identified 7 genes that have opposite expression trends in apoptotic treatments when compared with 8 different cancer types. In addition, based on structure similarity with 6 compounds that affect the expression patterns of these genes in a favorable way against 8 cancer types, we selected 23 natural compounds as suitable candidates for further tests as possible novel drugs or for the design of functional food for cancer treatment and prevention. Abstract: It is today widely accepted that a healthy diet is very useful to prevent the risk for cancer or its deleterious effects. Nutrigenomics studies are therefore taking place with the aim to test the effects Citation: Monticolo, F.; Chiusano, of nutrients at molecular level and contribute to the search for anti-cancer treatments. These efforts M.L. Computational Approaches for are expanding the precious source of information necessary for the selection of natural compounds Cancer-Fighting: From Gene useful for the design of novel drugs or functional foods.
    [Show full text]
  • Substitution Scanning Identifies a Novel, Catalytically Active Ibrutinib
    OPEN Leukemia (2017) 31, 177–185 www.nature.com/leu ORIGINAL ARTICLE Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant A Hamasy1,4, Q Wang1,4, KEM Blomberg1, DK Mohammad1,LYu2, M Vihinen3, A Berglöf1 and CIE Smith1 Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutations affecting BTK predominantly substitute cysteine 481 in the kinase domain for catalytically active serine, thereby ablating covalent binding of inhibitors. Activating substitutions in the BTK substrate phospholipase Cγ2 (PLCγ2) instead confers resistance independent of BTK. Herein, we generated all six possible amino acid substitutions due to single nucleotide alterations for the cysteine 481 codon, in addition to threonine, requiring two nucleotide substitutions, and performed functional analysis. Replacement by arginine, phenylalanine, tryptophan or tyrosine completely inactivated the catalytic activity, whereas substitution with glycine caused severe impairment. BTK with threonine replacement was catalytically active, similar to substitution with serine. We identify three potential ibrutinib resistance scenarios for cysteine 481 replacement: (1) Serine, being catalytically active and therefore predominating among patients. (2) Threonine, also being catalytically active, but predicted to be scarce,
    [Show full text]
  • Jenkins Meredith Msc 2019.Pdf
    Structural and Biochemical Investigation of the Regulation of Rab11a by the Guanine Nucleotide Exchange Factors SH3BP5 and TRAPPII by Meredith L Jenkins B.Sc. (Hons) Microbiology, University of Victoria, 2015 A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE in the Department of Biochemistry and Microbiology © Meredith L Jenkins, 2019 University of Victoria All rights reserved. This thesis may not be reproduced in whole or in part, by photocopy or other means, without the permission of the author. ii Supervisory Committee Structural and Biochemical Investigation of the Regulation of Rab11a by the Guanine Nucleotide Exchange Factors SH3BP5 and TRAPPII by Meredith L Jenkins B.Sc. (Hons) Microbiology, University of Victoria, 2015 Supervisory Committee Dr. John E Burke, Supervisor Department of Biochemistry and Microbiology Dr. Alisdair Boraston, Departmental Member Department of Biochemistry and Microbiology Dr. Robert Chow, Outside Member Department of Biology iii Abstract Rab11 is a critical GTPase involved in the regulation of membrane trafficking in the endocytic pathway, and it’s misregulation is involved in a variety of human diseases including Huntington’s disease and Alzheimer’s disease. Additionally, de novo mutations (DNMs) of Rab11 have been identified in patients with developmental disorders, and interestingly several parasites, viruses, and bacteria can subvert membrane trafficking through Rab11 positive vesicles to allow for replication and evasion from the immune system. Although Rab11 is one of the best characterized Rab GTPases, hindering the capability to completely understand Rab11 regulation and its role in human disease is the lack of detail describing how Rab11 proteins are activated by their cognate guanine nucleotide exchange factors (GEFs).
    [Show full text]
  • 1P31, 7Q21 and 18Q21 Chromosomal Aberrations and Candidate Genes in Acquired Vinblastine Resistance of Human Cervical Carcinoma KB Cells
    1155-1164 4/4/08 16:56 Page 1155 ONCOLOGY REPORTS 19: 1155-1164, 2008 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells JIN WANG1,3, LAI-SHAN TAI2, CHI-HUNG TZANG1, WAN FONG FONG1, XIN-YUAN GUAN2 and MENGSU YANG1 1Department of Biology and Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon; 2Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, P.R. China Received January 25, 2008; Accepted March 3, 2008 Abstract. Vinblastine (VBL) is used to treat certain kinds of resistance. This study also demonstrates that the combination cancer including Hodgkin's lymphoma, lung cancer, breast of CGH and cDNA microarray is a very useful tool to detect cancer, testicular cancer and cervical carcinoma. However, drug resistant targets in cancer treatment. the rapid development of resistance during therapy remains a major clinical challenge. In order to reverse cancer cell Introduction resistance, the goal of this study was to find differentially expressed genes and chromosomal alterations in multidrug Drug resistance is the major obstacle to be overcome during resistant (MDR) KB-v1 cells, further to probe the relation- the systemic therapy of cancer. The terms of drug resistance ship between drug resistance and differential genes, and and sensitivity are relative conditions that must be defined chromosomal changes in MDR cancer cells. Comparative with respect to some standard reference frames. Once a drug genomic hybridization (CGH) analysis of MDR KB-v1 and has achieved a critical threshold, it will interact with a range their parental KB-3-1 cells revealed chromosomal changes; of cellular macromolecules.
    [Show full text]
  • Profiling Cell Development by Gene Expression Characterization Of
    Characterization of Early Stages of Human B Cell Development by Gene Expression Profiling This information is current as Marit E. Hystad, June H. Myklebust, Trond H. Bø, Einar A. of September 28, 2021. Sivertsen, Edith Rian, Lise Forfang, Else Munthe, Andreas Rosenwald, Michael Chiorazzi, Inge Jonassen, Louis M. Staudt and Erlend B. Smeland J Immunol 2007; 179:3662-3671; ; doi: 10.4049/jimmunol.179.6.3662 Downloaded from http://www.jimmunol.org/content/179/6/3662 Supplementary http://www.jimmunol.org/content/suppl/2008/03/12/179.6.3662.DC1 Material http://www.jimmunol.org/ References This article cites 59 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/179/6/3662.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Characterization of Early Stages of Human B Cell Development by Gene Expression Profiling1 Marit E.
    [Show full text]